It comprises a process for the preparation of sitagliptin, or its pharmaceutically acceptable salts, or its solvates, including hydrates, comprising: a) coupling an halo-2,4,5-trifluorobenzene with a compound of formula (IV) to give N-protected sitagliptin; the coupling being carried out via the formation of an organocupric compound of the halo-2,4,5-trifluorobenzene or, alternatively, via the formation of a organozinc compound of a compound of formula (IV); where R1 is hydrogen or an amino protective group; R2 is an amino protective group; or alternatively R1 and R2 taken together form a phtalimido group; X is Br or I; and Y is r, I or R3SO2- wherein R3 is (C1-C4)-alkyl, phenyl, or phenyl mono- or disubstituted by a (C1-C4)-alkyl radical; b) submitting the N-protected sitagliptin to a deprotection reaction; and c) optionally its conversion into a pharmaceutically acceptable salt. It also comprises new intermediate compounds useful in such preparation process
本发明涉及一种制备
西格列汀、其药学上可接受的盐或其溶剂化物(包括
水合物)的方法,包括:a)偶联卤代2,4,5-三
氟苯与式(IV)化合物以得到N-保护基
西格列汀;偶联反应通过卤代2,4,5-三
氟苯的
有机铜化合物形成或者通过式(IV)化合物的
有机锌化合物形成进行;其中,R1为氢或
氨基保护基;R2为
氨基保护基;或者R1和R2组成邻苯二甲
酰亚胺基团;X为Br或I;Y为r、I或R3SO2-,其中R3为(C1-C4)烷基、苯基或由(C1-C4)烷基基团单取代或双取代的苯基;b)将N-保护基
西格列汀进行脱保护反应;c)可选地将其转化为药学上可接受的盐。本发明还包括在这种制备过程中有用的新中间化合物。